Table 1 Basic information of OMG patients in both the study group and the control group before treatment

Age (years)

49.0 + 19.2

49.5 + 22.6

0.09

0.92

Sex (Male/Female)

18/20

5/17

3.57

0.06

Ocular symptoms (type A/B/C)

2/16/4

12/20/6

4.01

0.13

Ptosis (binocular / monocular / none)

14/8/0

20/18/0

0.68

0.40

Number of paralyzed extraocular muscles (none/1/2/multiple).

6/3/9/4

18/5/11/4

2.62

0.45

Neostigmine test (positive/invisible)

17/5

29/9

0.007

0.93

Anti-achr-Ab (Positive/negative)

11/11

13/25

1.44

0.22

Electromyography (Positive/negative)

10/12

18/20

0.02

0.88

Presence of thymoma (Positive/negative)

3/19

3/35

0.65

Onset time (days)

34.2 + 33.5

28.7 + 19.9

0.71

0.48

Follow-up time (months)

22.2 + 7.53

22.7 + 7.55

0.24

0.81